NINDS Epilepsy Therapy Screening Program (ETSP) This contract will support the conduct of preclinical pharmacological evaluations of potential therapeutic agents (small molecules, natural products, synthetic peptides, biologics and referred to hereafter as ETSP “investigational compounds”) for the treatment of epilepsy and related disorders. The contract may also require evaluation of biomedical devices for the treatment of epilepsy and related disorders. This contract shall require the Contractor to conduct studies evaluating investigational compounds in the following performance areas: 1) established workflow for drug resistant epilepsy, 2) models of disease prevention and modification (anti-epileptogenesis), and 3) pharmacokinetic studies. In addition, the Contractor shall be required to perform ancillary studies and optional tasks to support the evolving requirements of the ETSP. The government expects the preponderance of work to be performed by the prime Contractor. Given factors including the complexity of the tasks, need for uniformity and consistency of results, protection of intellectual property rights, and management of controlled substances, the operational pieces must be well coordinated and controlled which is more likely to be successfully accomplished when the work is performed within the same organization. It is recognized that some subcontracting may be required where the Contractor does not have the capability to perform certain tasks in-house. In any event, the Contractor, despite the use of subcontracting shall be responsible for full and complete performance of all aspects of the Statement of Work (SoW).